Ionis Pharmaceuticals Inc
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.
What Analysts Think about Ionis
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders
Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.
Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.
What’s behind Biogen Buyout Rumors?
Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.
What Do Analysts Recommend for United Therapeutics?
23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”
Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.
A Look at Spectrum’s Financial Position in September
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.
Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.
Do Analysts See Any Upside for Ionis Stock?
Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”
Taking Stock of Ionis’s Performance
Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
A Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.
Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
A Look at Incyte’s Valuation on August 22
On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.
What Analysts Recommend for Ionis after Q2 2018
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.
How Ionis’s Q2 2018 Earnings Trended
Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.
Analysts Have Mixed Opinions about Ionis
Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.
Sage Therapeutics’ GABA Receptor–Based Products
On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?
In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.
Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.
Key Updates on Akcea Therapeutics’ Volanesorsen
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).
Exploring the Financial Performance of Akcea Therapeutics
In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.
Analysts’ Recommendations for Akcea and Its Peers in March
Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.
How Biogen’s Spinraza Is Positioned for 2018
In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.
Developments for Ionis Pharmaceuticals Post-3Q17
Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or nontherapeutic options.
A Look at Ionis’s 3Q17 Revenue Stream
Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.
Exploring Ionis’s 3Q17 Quarterly Revenue Trend
Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.
A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.
How Analysts Rated Jazz Pharmaceuticals in December
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals
On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.
Alnylam Is Preparing for Commercial Launch of Patisiran
To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.
Patisiran Expected to Become Key Growth Driver for Alnylam
Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.
What Analysts Recommend for Alnylam Pharmaceuticals and Peers
On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.
Geographic Market Expansion to Boost Spinraza Sales in 2017
In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.
Technology Platforms and Research Programs Drive LGND’s Partnerships
Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.
Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.
Ligand Pharmaceuticals’ Shots-on-Goal Business Model
Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.
Must-Know Developments for Ionis Pharmaceuticals
Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.
How Akcea Therapeutics’ Volanesorsen Performed in 2Q17
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.
Ionis Reports Revenue Growth in 2Q17
Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.
What’s Ionis Pharmaceuticals’ Valuation?
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.
Why Jazz Is Expected to Report a Robust Revenue Growth Rate
On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.
What Analysts Recommend for BioMarin Pharmaceuticals
A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”
What Analysts Recommend for United Therapeutics in June 2017
Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”
Developments for Ionis Pharmaceuticals after 1Q17
Ionis’s recent developments As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. Corporate developments In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China. In […]
Akcea Therapeutics’ Volanesorsen: 1Q17 Performance
Volanesorsen Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of Ionis, is engaged in pre-commercialization activities for volanesorsen, and will take care of the drug’s commercialization once it is approved by the FDA and the European Commission. The […]
Understanding Ionis Phamaceuticals’ Revenue Stream in 1Q17
Ionis Phamaceuticals’ revenue Ionis Pharmaceuticals (IONS) reported revenue of $110.3 million in 1Q17, 200% higher than its revenue of $36.9 million in 1Q16. Analysts estimate that its revenue will increase by over 100% to $78.9 million in 2Q17, mainly driven by growth in research and development revenue. Revenue performance The above graph shows Ionis’s revenue over the […]
Changes in Ionis Pharmaceuticals’ Valuation after 1Q17
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.
Novartis’s 1Q17 Earnings: Recent Developments
On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.
Ionis Pharmaceuticals’ Valuation Compared to Its Peers
According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
Novartis’s Recent Developments
Novartis (NVS) reported flat revenues at constant exchange rates during 4Q16 as well as in fiscal 2016. This was driven by growth in Sandoz revenues.
Why Is the ClearBridge Aggressive Growth Fund Lagging behind Peers?
SHRAX has been a below average YTD performer. The past year until October 14 was hard on the fund. It placed dead last among the 12 peers in this review.
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.
ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.
ALNY Reports Positive Results from Patisiran’s Open Label Extension Study
On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
What’s Ionis Pharmaceuticals Doing with IONIS-TTR?
In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.
A Look at Ionis Pharmaceuticals’ Nusinersen
Ionis Pharmaceuticals (IONS) has entered into a collaborative agreement with Biogen Idec (BIIB) for the development and commercialization of nusinersen.
Understanding Ionis Pharmaceuticals’ 2015 Revenue Stream
Ionis Pharmaceuticals (IONS) reported revenues of $284 million in 2015. Analysts are estimating that revenues will decline more than 16% to $237 million in 2016.
Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue
Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.
Ionis Pharmaceuticals: Valuation Compared to Its Peers
In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.
Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know
Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.